MiNK Therapeutics, Inc.
INKTNASDAQHealthcareBiotechnology
Previous close
$12.20
+$0.58 · +4.99%
INKT company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
28
Expensive
Momentum
32
Weakening
Sentiment
54
Mixed
Risk resilience
33
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteMiNK Therapeutics, Inc. is a biopharmaceutical firm currently undergoing clinical trials. Its primary focus is on the identification, advancement, and market introduction of innovative invariant natural killer T (iNKT) cell therapies. These treatments are allogeneic and designed to be "off-the-shelf," providing readily available options for combating various cancers and conditions rooted in immune system dysfunction. The company's leading investigational therapy is AGENT-797. This product is an allogeneic, ready-to-use iNKT cell therapy, presently in Phase 1 clinical studies to assess its effectiveness against different forms of myeloma. Established in 2017, the company was previously known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. is headquartered in New York, New York, and operates as a subsidiary of Agenus Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Jennifer S. Buell
- Listed since
- Oct 15, 2021
- Employees
- 15
Market position
Day range
Current $12.20
52-week range
Current $12.20
- Open
- $11.76
- Previous close
- $11.62
- Volume
- 11.78K
- 0.42× average
- Average volume
- 28.26K
- Average daily volume
- Market cap
- 60.78M USD
- Beta
- 0.48
- Market reference 1
- 50-day average
- $11.3056
- +7.91% above average
- 200-day average
- $11.4532
- +6.52% above average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 39.43M USD
- EV / EBITDA
- -3.2×
- Earnings yield
- -26.24%
- Free cash flow yield
- -12.45%
Profitability & efficiency
- Return on equity
- 87.82%
- Return on assets
- -87.75%
- Return on invested capital
- -195.52%
Financial health
- Current ratio
- 1.06×
Financial statements
Income trends
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 181.75K USD | 215.44K USD | 204.62K USD | 121.75K USD | 77.96K USD |
| Gross profit | −181.75K USD | −215.44K USD | −204.62K USD | −121.75K USD | −77.96K USD |
| Research and development | 5.76B USD | 6.34M USD | 15.49M USD | 23.12M USD | 13.97M USD |
| Selling, general, and administrative | 6.73B USD | 4.1M USD | 7.43M USD | 7.71M USD | 4.56M USD |
| Operating expenses | 12.31M USD | 10.43M USD | 22.72M USD | 30.83M USD | 18.53M USD |
| Interest income | 180.25K USD | 172.57K USD | 463.26K USD | 253.32K USD | 2.43K USD |
| Interest expense | — | — | — | 253.32K USD | 2.43M USD |
| Depreciation and amortization | 181.75K USD | 215.44K USD | 204.62K USD | 121.75K USD | 77.96K USD |
| Operating income | −12.49M USD | −10.65M USD | −22.92M USD | −30.95M USD | −18.61M USD |
| Net income | −12.49M USD | −10.78M USD | −22.46M USD | −27.99M USD | −30.21M USD |
Company facts updated Aug 24, 2026.
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Analyst price target
Average target
$35.00
186.89% upsideRating distribution
5 ratingsINKT news
INKT peers
ETFs holding INKT
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI- Market value
- 557.24K
- Weight
- 0.00%
- AUM
- 2.3T USD
- Expense ratio
- 0.03%
- Price / 1D
- $378.24+0.44%
Vanguard Extended Market ETFVXF- Market value
- 161.51K
- Weight
- 0.00%
- AUM
- 93.7B USD
- Expense ratio
- 0.05%
- Price / 1D
- $245.53+0.82%
iShares Micro-Cap ETFIWC- Market value
- 79.27K
- Weight
- 0.01%
- AUM
- 1.53B USD
- Expense ratio
- 0.60%
- Price / 1D
- $198.39+1.10%
Continue in GoAI
Research INKTresearch.disclaimer